Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

) in late April, InterMune, Roche and Pharmasset, Inc. reported top-line results from the novel Phase 1 INFORM-1 clinical trial evaluating ITMN-191 in combination with nucleoside polymerase inhibitor R7128 but no interferon or ribavirin in patients with HCV infection. Data from the first four dosage cohorts of the study were as follows:
  • The combination resulted in sustained viral load reductions over the dosing period in all cohorts. Seventy percent (70%) of patients in the last two dosage cohorts had levels of virus in their blood below the limit of quantification by the diagnostic assay at day 14, and 33% of these patients had no detectable virus in their blood at day 14.
  • Patients receiving the combination of ITMN-191 and R7128 for 14 days experienced a median reduction in viral levels of -4.8 to -5.2 Log10 IU/mL in the last two cohorts tested.
  • In the early low-dose groups, after only three days of dosing, the mean reduction in viral load levels was 0.6 log10 greater with combination treatment (-2.9) compared to the performance of the individual compounds when given as monotherapy (-0.46 and -1.84 for R7128 and R7227, respectively).
  • The combination was well tolerated over 14 days, with no treatment-related serious adverse events (SAEs), dose reductions or discontinuations. Pharmacokinetic analysis confirmed that there were no drug-drug interactions between the compounds.

  • On April 21, InterMune reported that based on these promising early results, the INFORM-1 study had been expanded to explore the interferon-free regimen in treatment-experienced patients; both treatment failures and null-responder HCV patients and would include twice-daily dosing of ITMN-191 and significantly higher total daily doses (600mg and 900mg twice daily) than those explored in the first four patient cohorts of
    '/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 The Academy of Model Aeronautics ... led by Indiana Gov. Mike Pence, has declared August ... will host a Family Fest and aviation themed Motorcycle ... benefit the Wounded Warrior Project. , National Model Aviation ... Aeronautics—the country’s foremost organization for model aviation—to celebrate the ...
(Date:5/5/2015)... 5, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... , President and Chief Executive Officer, will present ... DATE:  Thursday, May 7, 2015     TIME:  11:30 am ... > click the red "register/ watch presentations" button ... online event where investors are invited to ask ...
(Date:5/5/2015)... 05, 2015 Franz Inc ., the ... announced that its flagship product, AllegroGraph, has been named a ... Market Update report. AllegroGraph is a high performance ... industry standards. Graph databases are skyrocketing in popularity and have ... a recent DBMS ranking by DB-Engines. , “We ...
(Date:5/5/2015)... 5, 2015 CytomX, a biotechnology company developing ... that Sean McCarthy , D. Phil., chief executive ... in New York at 1:15 ... present an overview of CytomX,s Probody pipeline, including the ... About CytomX Therapeutics CytomX Therapeutics develops ...
Breaking Biology Technology:State of Indiana proclaims August 15 as Model Aviation Day 2ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3
... Saladax Biomedical, Inc., a privately held company developing ... of personalized medicine for new and existing therapeutics, announced ... M.D., M.S. has been elected as chairman for the ... a board certified pathologist with more than 20 years ...
... July 6, 2011 As part of its ongoing ... moderate healthcare costs for patients diagnosed with scoliosis, Axial ... development of molecular diagnostic technologies, today announced that it ... for Children ® . The agreement ...
... AMSTERDAM, July 6, 2011 ,   ... in,the field of human gene therapy, today announced the ... Dr. Camozzi brings,to AMT more than 25 years of ... This includes,overseeing product approvals at the European Medicines Agency ...
Cached Biology Technology:Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Company's Board of Directors 2Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Company's Board of Directors 3Axial Biotech Signs Agreement With Shriners Hospital for Children 2Axial Biotech Signs Agreement With Shriners Hospital for Children 3Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer 2Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer 3
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... The American Association for Cancer Research announces the ... which will publish high-impact, peer-reviewed articles describing major advances ... feature game-changing research, review articles, perspectives and commentaries, news, ... Cancer Discovery is a new addition to the ...
... issued today by the International AIDS Society, Universal Access: ... around universal access during the XVIII International AIDS Conference (AIDS ... and reveals the scale of the future challenge for HIV ... outstripping those receiving treatment by five to two. ...
... international team of Mycologists and Ecologists studying Atlantic sea turtles ... threat from a fungal infection which targets eggs. The research, ... the fungus Fusarium solani may have played a ... "In the past 30 years we have witnessed an ...
Cached Biology News:AACR announces new journal, Cancer Discovery 2New report underlines the threat to universal access to HIV prevention, treatment and care due to a slow-down in treatment scale-up and waning political will 2New report underlines the threat to universal access to HIV prevention, treatment and care due to a slow-down in treatment scale-up and waning political will 3Atlantic sea turtle population threatened by egg infection 2
... FL is equipped with ... measurement technologies that complement ... advanced features of Fluoroskan ... Fluoroskan Ascent FL provides ...
... is a hydrolytic enzyme that catalyzes ... of glucose, maltose, maltotriose and,dextrins. The ... of the human,body are of clinical ... important enzymes for industry.4, The EnzChek ...
... new Class II safety cabinets Heraeus HERAsafe KS ... user-orientated design. ,The new frameless slanted window ... area. The new front window design makes it ... large work aperture with a height of more ...
... is a high-quality four-place microplate shaker with ... speed is adjustable from 100 to 1350 ... a small orbit ensure effective shaking for ... quick and easy to set for 0 ...
Biology Products: